{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:24:47Z","timestamp":1791645887051,"version":"4.3.4"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Noninfectious uveitis (NIU), which pathogenesis is often autoimmune nature, occurs as a symptom of systemic syndromes or only in the eye. The standard treatment of NIU is local, topical, and oral administration of corticosteroids (CS) in combination with immunomodulatory therapy (IMT). However, additional therapeutic strategies involving topical and systemic administration of CS or others to treat relapse or exacerbation of ocular inflammation in NIU which present as various ocular manifestations have not been established. The aim of this study was to investigate therapeutic strategies used for various ocular inflammations in relapse or exacerbation of NIU and to evaluate factors associated with the treatment pattern in Japan. The subjects were 198 eyes of 156 NIU patients with relapse or exacerbation of ocular inflammation at 6 university hospitals in Japan. The most frequent disease was sarcoidosis in 23.7% of the cases, followed by Beh\u00e7et disease (BD) in 21.2%, Vogt-Koyanagi-Harada (VKH) disease in 13.6%, acute anterior uveitis (AAU) in 5.6%, tubulointerstitial nephritis and uveitis syndrome (TINU) in 4.0%, and juvenile idiopathic arthritis (JIA)-associated uveitis in 3.0%. Common ocular findings were worsened anterior inflammation (AI) in 67.2% of the cases, vitreous opacity (VO) in 46.5%, macular edema (ME) in 26.8%, retinal vasculitis (RV) in 23.7%, serous retinal detachment (SRD) in 9.1%, and optic perineuritis (OPN) in 4.0%. Reinforcement of betamethasone eye drop (ED) monotherapy for only AI in both unilateral and bilateral AI, sub-tenon injection of triamcinolone acetonide (STTA) for unilateral posterior inflammation including VO and ME, and systemic therapy using CS and\/or IMT for bilateral anterior and posterior inflammation were significantly more frequent. Frequencies of exacerbated individual ocular findings in sarcoidosis and BD were similar, and severe ocular inflammation associated with panuveitis required both topical and systemic therapies. These results demonstrate that reinforcement of betamethasone EDs, topical administration of triamcinolone acetonide, and long-term administration of systemic corticosteroids are the major therapeutic strategies, and reinforcement of betamethasone EDs was used for exacerbated AI independently from its use for posterior inflammation. In addition, STTA was preferentially used for VO and ME associated with posterior inflammation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014668","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T20:42:28Z","timestamp":1551386548000},"page":"e14668","source":"Crossref","is-referenced-by-count":14,"title":["Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan"],"prefix":"10.1097","volume":"98","author":[{"given":"Masaru","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, National Defense Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Defense Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Kaburaki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Tokyo School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Tokyo School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Namba","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koju","family":"Kamoi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Tokyo Medical and Dental University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuichi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Yokohama City University School of Medicine, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Mizuki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Science, Tokyo Medical and Dental University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archopht.1962.00960030506014","article-title":"Epidemiology of uveitis: incidence and prevalence in a small urban community","volume":"68","author":"Darrell","year":"1962","journal-title":"Arch Ophthalmol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/09273949409057073","article-title":"Epidemiology of uveitis in Switzerland","volume":"2","author":"Tran","year":"1994","journal-title":"Ocul Immunol Inflamm"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0420.1997.tb00255.x","article-title":"Incidence and prevalence of different uveitis entities in Finland","volume":"75","author":"P\u00e4iv\u00f6nsalo-Hietanen","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in Northern California: the Northern California epidemiology of uveitis study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ajo.2008.09.014","article-title":"Incidence and prevalence of uveitis in veterans affairs medical centers of the Pacific Northwest","volume":"146","author":"Suhler","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaophthalmol.2013.4237","article-title":"Incidence and prevalence of uveitis: results from the pacific ocular inflammation study","volume":"131","author":"Acharya","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00005792-200107000-00005","article-title":"Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center","volume":"80","author":"Bodaghi","year":"2001","journal-title":"Medicine"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2007.132621","article-title":"Treatment of ocular inflammatory conditions with loteprednol etabonate","volume":"92","author":"Pavesio","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000078612","article-title":"Uveitis: a potentially blinding disease","volume":"218","author":"Durrani","year":"2004","journal-title":"Ophthalmologica"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.iae.0000250601.15893.5f","article-title":"Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion","volume":"Suppl","author":"Nguyen","year":"2006","journal-title":"Retina"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/00002512-200623070-00001","article-title":"Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology and management","volume":"23","author":"Gupta","year":"2006","journal-title":"Drugs Aging"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.ophtha.2017.06.017","article-title":"Corticosteroid-related adverse events systematically increase with corticosteroid dose in noninfectious intermediate, posterior, or panuveitis: post hoc analyses from the VISUAL-1 and VISUAL-2 trials","volume":"124","author":"Suhler","year":"2017","journal-title":"Ophthalmology"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/OPTH.S121734","article-title":"A review and update on orphan drugs for the treatment of non infectious uveitis","volume":"11","author":"You","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5301\/ejo.5000278","article-title":"Review on the worldwide epidemiology of uveitis","volume":"23","author":"Miserocchi","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/383787a0","article-title":"Functional diversity of helper T lymphocytes","volume":"383","author":"Abbas","year":"1996","journal-title":"Nature"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/09286580802262821","article-title":"Demographic and clinical features of uveitis in tertiary centers in Turkey","volume":"15","author":"Kazokoglu","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/02713680500263606","article-title":"Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China","volume":"30","author":"Yang","year":"2005","journal-title":"Curr Eye Res"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10384-006-0383-4","article-title":"Epidemiological survey of intraocular inflammation in Japan","volume":"51","author":"Goto","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s10384-012-0158-z","article-title":"The 2009 prospective multi-center epidemiologic survey of uveitis in Japan","volume":"56","author":"Ohguro","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2003.07.018","article-title":"Comparison of patients with Beh\u00e7et's disease in the 1980s and 1990s","volume":"111","author":"Yoshida","year":"2004","journal-title":"Ophthalmology"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s004170050235","article-title":"Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects","volume":"237","author":"Lafranco Dafflon","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ajo.2011.02.009","article-title":"Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis","volume":"152","author":"Leder","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/09273948.2013.767353","article-title":"Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis","volume":"21","author":"Salek","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(14)73759-6","article-title":"The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis","volume":"120","author":"Helm","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"1916.e1","DOI":"10.1016\/j.ophtha.2005.06.009","article-title":"Outcome of intravitreal triamcinolone in uveitis","volume":"112","author":"Kok","year":"2005","journal-title":"Ophthalmology"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/09273940590933511","article-title":"Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema","volume":"13","author":"Androudi","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/09273940600826604","article-title":"Intravitreal triamcinolone acetonide injection for the treatment of posterior uveitis","volume":"14","author":"Ozkiris","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10384-009-0692-5","article-title":"Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes","volume":"53","author":"Hirano","year":"2009","journal-title":"Jpn J Ophthalmol"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"R34-20230914","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(83)90230-1","article-title":"Treatment of intraocular inflammatory disease with cyclosporin A","volume":"2","author":"Nussenblatt","year":"1983","journal-title":"Lancet"},{"key":"R35-20230914","first-page":"146","article-title":"Cyclosporin A in the treatment of posterior uveitis","volume":"104","author":"Graham","year":"1985","journal-title":"Trans Ophthalmol Soc U K"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0171-2985(97)80040-X","article-title":"Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation","volume":"198","author":"Ruhlmann","year":"1997","journal-title":"Immunobiology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201903010-00032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:38:04Z","timestamp":1694716684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201903010-00032"}},"subtitle":["A multicenter study"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014668","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}